ArticleJournal of diabetes investigation2018
Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both?
Article in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Trial
- Adipokine-Cytokine Profile in Patients with Unstable Atherosclerotic Plaques and Abdominal Obesity.International journal of molecular sciences · 2023Article
- Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity.Journal of diabetes investigation · 2022Review
- Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus.Environmental science and pollution research international · 2022Review
- Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment.International journal of women's health · 2022Review
- Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents.The Journal of clinical endocrinology and metabolism · 2021Article
- The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.Therapeutic advances in endocrinology and metabolism · 2021 · on this mapReview
- A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes.Nutrients · 2020Review
- Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men.Endocrinology, diabetes & metabolism · 2020Article
- The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.Diabetologia · 2019Article
- The journey to understanding incretin systems: Theory, practice and more theory.Journal of diabetes investigation · 2019Article
- Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult.Journal of diabetes research · 2019Article
- Observational
- Novel Antidiabetic Medications in Polycystic Ovary Syndrome.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incretins comprise a pair of gut hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which are secreted in response to food ingestion and enhance glucose-dependent insulin secretion from pancreatic β-cells. Immediately after secretion, GLP-1 is degraded by dipeptidyl peptidase-4 more rapidly than GIP, and circulating levels of biologically intact GLP-1 are substantially lower than those of biologically intact GIP. Therefore, there has been a debate on how the gut-derived GLP-1 exerts insulinotropic actions. Recent publications have revealed two novel mechanisms by which GLP-1 exerts insulinotropic actions: (i) the gut-derived GLP-1 activates receptors expressed in nodose ganglions, thereby potentiating glucose-dependent insulin secretion through the vagus nerves; and (ii) the pancreatic α-cell-derived GLP-1 activates receptors expressed in β-cells in a paracrine manner. While the relative contributions of the two mechanisms under normal and pathological conditions remain unknown and mechanisms regulating GLP-1 secretion from α-cells need to be investigated, the available data strongly indicate that the effects of GLP-1 on insulin secretion are far more complex than previously believed, and the classical incretin concept regarding GLP-1 should be revised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.